Highest-materiality recent filing
Oruka names Todd Edwards Chief Commercial Officer, eff. Aug 24 2026
Todd Edwards, ex-CCO of Arcutis Biotech, starts as Oruka's Chief Commercial Officer on Aug 24, 2026, reporting to CEO.
Oruka Q2 net loss $41.2M; EVERLAST-A 63.5% PASI 100; cash $1.1B
Q2 2026 net loss $41.2M vs $24.6M in Q2 2025; R&D spend $43.3M; cash $1.1B funds through BLA filing.
Lawrence Klein (43.9M votes for) and Chris Martin (43.9M for) elected as Class II directors; 1.3M broker non-votes.
Oruka amended IL-23 license with Paragon to expand field to include inflammatory bowel disease (IBD).
Oruka Therapeutics closes 9.66M-share offering at $72.50; prelim cash $496M
Oruka completed underwritten public offering of 9,660,000 shares of common stock at $72.50 per share, raising gross proceeds of approximately $700 million.
Oruka Phase 2a EVERLAST-A meets primary endpoint: 63.5% PASI 100 at Week 16 in psoriasis
ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 vs 4.8% placebo (p<0.0001), exceeding primary endpoint.
Oruka Therapeutics appoints Christopher Martin to board; Cameron Turtle resigns
Cameron Turtle resigned as director on Dec 11, 2025; not due to disagreement with the company.
Oruka raises $180M; ORKA-001 Phase 1 shows ~100-day half-life, supports annual dosing
Private placement gross proceeds ~$180M; issued 10.9M shares at $15.00 and pre-funded warrants for 1.07M shares.
Oruka Therapeutics appoints Laura Sandler as COO, effective July 1, 2025
Base salary of $460,000 per year; eligible for annual bonus targeted at 40% of base.
Oruka Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay
Elected Carl Dambkowski (26,047,914 for) and Peter Harwin (25,935,823 for) as Class I directors.
Oruka Therapeutics licenses IL-17A/F antibodies from Paragon; up to $22M in milestones
Exclusive worldwide license to develop and commercialize Paragon's anti-IL-17A/F antibodies.
Oruka Therapeutics enters exclusive IL-23 license with Paragon; up to $22M milestones
Oruka grants exclusive worldwide license for anti-IL-23 antibodies (ORKA-001) from Paragon, excluding inflammatory bowel disease.
Oruka shareholders approve Series A conversion and adjournment proposals
30,598,476 shares voted for Series A conversion; 6,026 against; 1,089 abstaining; no broker non-votes.
Oruka files retroactively adjusted pre-merger audited financials as of Feb 6, 2024
Balance sheet shows $1K subscription receivable, zero cash; total stockholders' equity $1K.
Oruka Therapeutics amends CEO & SVP employment agreements, revising severance terms
CEO Klein: outside CIC, severance = 12 months base salary + 30% time-based equity vesting. Within CIC, 1.5x base+bonus + full equity acceleration.
Oruka raises $200M via PIPE; accelerates ORKA-001/002 clinical timelines
Gross proceeds of ~$200M from sale of common stock, preferred stock, and pre-funded warrants at $23.00 per common share.
ARCA completes reverse merger with Oruka; combined entity renamed Oruka Therapeutics (ORKA)
Merger closed: ARCA (shell) merges with private Oruka; Oruka shareholders own ~97.6% of combined company.
ARCA sets special dividend at $1.613/share for Oruka merger; ex-date Aug 29
Special cash dividend of $1.613 per share payable on Aug 28 to holders of record Aug 26.
Shareholders approved all 9 proposals at Aug 22 special meeting, including merger, share increase to 545M, and reverse split.
ARCA biopharma declares special dividend of $1.59/share in connection with proposed Oruka merger
Special dividend estimated at $1.59 per share, payable to stockholders of record as of August 26, 2024.
ARCA biopharma sells legacy Gencaro and rNAPc2 assets to Genvara for $300K
ARCA entered Asset Purchase Agreement with Genvara Biopharma to sell all rights in Gencaro (bucindolol) for atrial fibrillation and rNAPc2 (AB201) for COVID-19.
ARCA biopharma Q2 net loss widens to $2.7M, cash $33.3M; merger with Oruka ongoing
Net loss $2.7M ($0.18/sh) vs $1.5M ($0.10) in Q2 2023, driven by $1.3M increase in G&A expenses.
Oruka Therapeutics fixes purchase price error, adds employee warrants in merger with ARCA
July 3, 2024: Oruka and parties signed Letter Agreement correcting a scrivener's error in the Purchase Price definition.
ARCA biopharma Q1 net loss $2.0M, cash $35.9M; Oruka merger and CEO change detailed
Net loss for Q1 2024 was $2.0M ($0.14 per share) vs $1.3M ($0.09) in Q1 2023.
ARCA biopharma boosts CEO and CFO retention bonuses to $200K each
Board approved 33.33% increase in retention bonuses for Thomas A. Keuer and C. Jeffrey Dekker to $200,000 each.
CEO Michael Bristow departs ARCA biopharma; COO Thomas Keuer named President
Dr. Bristow's employment and board membership ended April 3, 2024 by mutual agreement, not due to any disagreement.
ARCA biopharma to merge with Oruka; Oruka holders to own ~97.6% of combined company
Oruka stockholders to own ~97.62% of the combined company; ARCA stockholders ~2.38%.
ARCA biopharma extends headquarters lease through September 2024 at increased rent
Lease extended 6 months to Sept 30, 2024; base rent raised to $8,206.42/month from April 1.
Two ARCA biopharma directors resign; board reduced from eight to six
Raymond L. Woosley and Dan Mitchell resigned from ARCA biopharma board effective Feb 2, 2024.
ARCA biopharma posts 2023 net loss of $5.3M ($0.37/share); cash $37.4M
Net loss improved to $5.3M from $9.9M in 2022; basic EPS loss $0.37 vs $0.69.
Board granted options to purchase 6,000 shares each to 7 non-employee directors at $1.64 per share, vesting monthly over 12 months.
ARCA biopharma sets Jan 30, 2024 annual meeting, Dec 6 record date, Dec 11 proposal deadline
Annual meeting scheduled for January 30, 2024; record date for voting is December 6, 2023.
ARCA biopharma increases retention bonuses for two execs by 50% to $150,000 each
Retention bonus for Thomas Keuer and C. Jeffrey Dekker increased 50% to $150,000 each.
ARCA biopharma reports Q3 2023 net loss of $1.4M; cash $38.5M sufficient through end of 2024
Net loss of $1.4M ($0.10/share) vs $2.3M ($0.16/share) in Q3 2022; operating expenses down to $2.0M from $2.6M.
ARCA biopharma Q2 2023 net loss $1.5M; cash $40.2M; strategic review continues
Net loss $1.5M ($0.10/sh) vs $3.1M ($0.22) in Q2 2022; total operating expenses $2.0M vs $3.2M.
ARCA biopharma reports Q1 net loss of $1.3M; strategic review ongoing
Net loss of $1.3M ($0.09 per share) vs $3.3M ($0.23) in Q1 2022; improvement due to lower R&D costs.
ARCA biopharma reports FY2022 net loss of $9.9M; cash $42.4M; strategic review ongoing
Net loss $9.9M ($0.69/share) vs $19.3M ($1.39/share) in 2021; operating expenses down to $10.6M from $19.3M.
ARCA biopharma General Counsel Christopher Ozeroff to depart effective March 31, 2023
Christopher D. Ozeroff, Secretary, SVP and General Counsel, to leave ARCA biopharma effective March 31, 2023.
ARCA biopharma elects James Flynn to Board; annual meeting results
James Flynn elected to Board for term ending 2025 under cooperation agreement with Cable Car Capital.
ARCA biopharma awards $100K retention bonuses and 40K RSUs each to COO Keuer and CFO Dekker
COO Thomas Keuer and CFO C. Jeffrey Dekker each receive $100,000 cash retention bonus and 40,000 RSUs.
ARCA biopharma Q3 net loss narrows to $2.3M; strategic review with workforce reduction
Net loss of $2.3M ($0.16/sh) narrowed from $4.7M ($0.33/sh) in Q3 2021.
ARCA biopharma sets 2022 annual meeting for Dec 15, record date Oct 25
Shareholder proposals/nominations due by Oct 24, 2022 due to meeting being >30 days from prior year.
ARCA biopharma Q2 net loss narrows to $3.1M; strategic review ongoing
Net loss $3.1M ($0.22/sh) vs $4.8M ($0.34/sh) year ago.
Jacob Ma-Weaver appointed as Class III director effective June 15, 2022, term through 2024 annual meeting.
ARCA biopharma retains Ladenburg Thalmann for strategic options review
Retained Ladenburg Thalmann & Co. Inc. as financial advisor for strategic review.
ARCA biopharma Q1 net loss narrows to $3.3M; initiates strategic review
Net loss of $3.3M ($0.23/share) vs $4.1M ($0.33/share) in Q1 2021, narrowing on lower R&D spend.
ARCA biopharma establishes Special Committee to evaluate strategic options
Special Committee formed to explore options for maximizing stockholder value.
ARCA biopharma's rNAPc2 fails to meet primary endpoint in Phase 2b COVID-19 trial
Pooled rNAPc2 reduced D-dimer 16.8% vs heparin 11.2% (P=0.47), missing statistical significance.
ARCA biopharma reports FY2021 net loss $19.3M, cash $53.4M; rNAPc2 data due late March 2022
Net loss $19.3M ($1.39/share) vs $9.7M ($2.07/share) in FY2020; total operating expenses $19.3M.
ARCA biopharma awards incentive stock options to four executives
CEO Michael Bristow received 95,000 options; COO Keuer 35,000; GC Ozeroff 27,500; CFO Dekker 17,700.
the Board appointed Thomas A. Keuer, the Company’s Chief Operating Officer, to serve as ARCA’s President and principal executive officer.
Dr. Michael Bristow, President, Chief Executive Officer and a member of the board of directors (the “Board”) of ARCA have mutually agreed to conclude Dr. Bristow’s employment and service as a director, effective April 3, 2024.
On February 2, 2024, Raymond L. Woosley, M.D., Ph.D. and Dan Mitchell each resigned from the board of directors (the “ Board ”) of ARCA biopharma, Inc., a Delaware corporation (“ ARCA ”), effective immediately.
On February 2, 2024, Raymond L. Woosley, M.D., Ph.D. and Dan Mitchell each resigned from the board of directors (the “ Board ”) of ARCA biopharma, Inc., a Delaware corporation (“ ARCA ”), effective immediately.
ARCA biopharma, Inc. (“ARCA” or the "Company") and Christopher D. Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA have mutually agreed to conclude Mr. Ozeroff’s employment effective March 31, 2023.
On December 15, 2022, the Board of Directors (the “Board”) of ARCA biopharma, Inc. (the “Company”) elected James Flynn, as a director of the Company.
On June 15, 2022, the Board of the Company elected Jacob Ma‐Weaver as a director of the Company.
Max materiality 0.90 · Median 0.60 · Most common event other_material